JP2022526656A - 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 - Google Patents

治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 Download PDF

Info

Publication number
JP2022526656A
JP2022526656A JP2021559853A JP2021559853A JP2022526656A JP 2022526656 A JP2022526656 A JP 2022526656A JP 2021559853 A JP2021559853 A JP 2021559853A JP 2021559853 A JP2021559853 A JP 2021559853A JP 2022526656 A JP2022526656 A JP 2022526656A
Authority
JP
Japan
Prior art keywords
compound
polymer
amorphous
dispersion
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021559853A
Other languages
English (en)
Japanese (ja)
Inventor
ジェイ ガーミス，ロバート
カラニ レボンズ，ジャクアン
プールナ レディ，ジャイ
ジェイ ステファンスキー，ケビン
エム ワクニス，ブルシャリ
エム ジーンバ，テリーサ
サクセナ，アジャイ
コラバディ スリダル，スリカント
シン チョワン，ガジェンドラ
パル，シャルミスタ
パッタッセリ，シェビーラリ
ナラシマムルティ，ルーパ
スワミー パンドゥランガ，ナラヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022526656A publication Critical patent/JP2022526656A/ja
Priority to JP2025083936A priority Critical patent/JP2025131625A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021559853A 2019-04-11 2020-04-10 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 Withdrawn JP2022526656A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025083936A JP2025131625A (ja) 2019-04-11 2025-05-20 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
US62/832,606 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025083936A Division JP2025131625A (ja) 2019-04-11 2025-05-20 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能

Publications (1)

Publication Number Publication Date
JP2022526656A true JP2022526656A (ja) 2022-05-25

Family

ID=70465560

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559853A Withdrawn JP2022526656A (ja) 2019-04-11 2020-04-10 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能
JP2025083936A Pending JP2025131625A (ja) 2019-04-11 2025-05-20 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025083936A Pending JP2025131625A (ja) 2019-04-11 2025-05-20 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能

Country Status (18)

Country Link
US (2) US12509461B2 (https=)
EP (1) EP3953355A1 (https=)
JP (2) JP2022526656A (https=)
KR (1) KR20210151183A (https=)
CN (1) CN113924300A (https=)
AR (1) AR118650A1 (https=)
AU (2) AU2020271103B2 (https=)
BR (1) BR112021020257A2 (https=)
CA (1) CA3132530A1 (https=)
CL (1) CL2021002627A1 (https=)
CO (1) CO2021015054A2 (https=)
EA (1) EA202192753A1 (https=)
IL (1) IL287103A (https=)
MX (2) MX2021012288A (https=)
PE (1) PE20212367A1 (https=)
SG (1) SG11202111131VA (https=)
TW (1) TW202104228A (https=)
WO (1) WO2020210629A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023010629A (es) 2021-03-09 2023-09-19 Bayer Ag Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida.
TW202327607A (zh) 2021-09-17 2023-07-16 美商必治妥美雅史谷比公司 用於預防及治療血管栓塞病症之米爾維仙(milvexian)
UY40381A (es) 2022-08-01 2024-01-31 Janssen Pharmaceutica Nv Uso de milvexian para el tratamiento o la prevención del accidente cerebrovascular isquémico
CN120712076A (zh) 2023-02-06 2025-09-26 百时美施贵宝公司 米尔维仙药物组合物
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11116502A (ja) * 1997-08-11 1999-04-27 Pfizer Prod Inc 噴霧乾燥固体分散系を含む組成物
JP2017530157A (ja) * 2014-10-01 2017-10-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのピリミジノン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569786A (da) 1985-11-27 1987-05-28 Syntex Inc Benzimidazolderivater
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
KR101739994B1 (ko) * 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
CN116987080A (zh) * 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
PT3445767T (pt) 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11116502A (ja) * 1997-08-11 1999-04-27 Pfizer Prod Inc 噴霧乾燥固体分散系を含む組成物
JP2017530157A (ja) * 2014-10-01 2017-10-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのピリミジノン

Also Published As

Publication number Publication date
AU2020271103A1 (en) 2021-12-02
IL287103A (en) 2021-12-01
US20220144835A1 (en) 2022-05-12
US20260042761A1 (en) 2026-02-12
AU2020271103B2 (en) 2026-01-08
WO2020210629A1 (en) 2020-10-15
AU2025279715A1 (en) 2026-01-15
AR118650A1 (es) 2021-10-20
PE20212367A1 (es) 2021-12-21
TW202104228A (zh) 2021-02-01
MX2025011559A (es) 2025-11-03
SG11202111131VA (en) 2021-11-29
US12509461B2 (en) 2025-12-30
JP2025131625A (ja) 2025-09-09
EP3953355A1 (en) 2022-02-16
EA202192753A1 (ru) 2022-01-11
CO2021015054A2 (es) 2021-11-19
MX2021012288A (es) 2021-11-12
CA3132530A1 (en) 2020-10-15
CL2021002627A1 (es) 2022-05-06
BR112021020257A2 (pt) 2021-12-07
KR20210151183A (ko) 2021-12-13
CN113924300A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
JP2022526656A (ja) 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
JP7469304B2 (ja) Ｐａｒｐインヒビタを含む医薬組成物
CA3019257C (en) A pharmaceutical formulation of palbociclib and a preparation method thereof
CN108938583B (zh) 包含无定形达格列净的制剂
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
JP7333340B2 (ja) 高い活性薬剤ローディングを有する固体剤形
WO2022141665A1 (zh) 一种水溶性大麻素制剂及其制备方法
US5906991A (en) Process for the manufacture of flavanolignan preparations with improved release and absorbability, compositions obtainable thereby and their use for the preparation of pharmaceuticals
EA028329B1 (ru) Содержащая прасугрель стабильная фармацевтическая лекарственная форма с немедленным высвобождением для перорального введения, способ получения и применения
EA052985B1 (ru) Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме
US20050118265A1 (en) Antifungal oral dosage forms and the methods for preparation
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
EP4251271A1 (en) Direct compression method for non-micronised apixaban formulations
WO2026035689A1 (en) Vamorolone solid oral dosage forms
KR100432949B1 (ko) 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법
WO2022115052A1 (en) Improved wet granulation processes for apixaban comprising formulations
HK40025159B (en) Orally administrable enzalutamide-containing pharmaceutical composition
HK40004093A (en) Pharmaceutical preparation of palbociclib and preparation method thereof
HK40025159A (en) Orally administrable enzalutamide-containing pharmaceutical composition
HK1170166B (en) Pharmaceutical composition for improving solubility of prasugrel and its preparation method
HK1170166A1 (en) Pharmaceutical composition for improving solubility of prasugrel and its preparation method

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240909

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250701